

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Tarlatamab for previously treated advanced small-cell lung cancer [ID6364]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
<p>The technical team notes:</p> <ul style="list-style-type: none">• Lung cancer incidence is strongly related to age. The highest rates are in in the 75 to 79 age group for females and the 85 to 89 age group for males.• Lung cancer incidence is higher in people of European family origin (compared to people of African or Asian origin) <p>The company state "It is not anticipated that there will be any equality or equity issues with the draft remit and scope".</p>

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
Issues related to differences in prevalence or incidence of a disease cannot normally be addressed in a technology appraisal recommendation.

3. Has any change to the draft scope been agreed to highlight potential equality issues?
No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No

Approved by Associate Director (name):Linda Landells...

Date: 29 February 2024